CanBas Co logo

4575 - CanBas Co Share Price

¥687 22.0  3.3%

Last Trade - 03/07/20

Micro Cap
Market Cap £35.4m
Enterprise Value £33.1m
Revenue £821k
Position in Universe 3052nd / 3866
Unlock 4575 Revenue
Relative Strength (%)
1m -7.75%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 61.0 105.2 109.9 110 115.6
Balance Sheet
FINANCIAL BRIEF: : For the nine months ended 31 March 2020, CanBas Co Ltd (Parent) revenues decreased 6% to Y82.6M. Net loss applicable to common stockholders increased 17% to Y405.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Selling, general and administratibe expe increase of 15% to Y177.6M (expense), Interest expenses increase from Y850K to Y1.9M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


4575 Revenue Unlock 4575 Revenue

Net Income

4575 Net Income Unlock 4575 Revenue

Normalised EPS

4575 Normalised EPS Unlock 4575 Revenue

PE Ratio Range

4575 PE Ratio Range Unlock 4575 Revenue

Dividend Yield Range

4575 Dividend Yield Range Unlock 4575 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
4575 EPS Forecasts Unlock 4575 Revenue
Profile Summary

CanBas Co., Ltd. is engaged in research and development of anticancer drugs which have little influence to the normal cells. In the general medicinal products development process, the Company is engaged in the exploration of compounds in accordance with the medicinal products subjects; the improvement of the compounds; the verification of the compounds on the animals; the application of investigational new drug (IND), as well as the initial stage of clinical investigation which tests the compounds on humans. The Company's developing items include CBP501, CBS9106 and others.

Last Annual June 30th, 2019
Last Interim March 31st, 2020
Incorporated January 18, 2000
Public Since September 17, 2009
No. of Shareholders: n/a
No. of Employees: 13
Sector Healthcare
Industry Pharmaceuticals
Exchange Tokyo Stock Exchange
Shares in Issue 6,910,604
Free Float (0.0%)
Eligible for
4575 Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for 4575
Upcoming Events for 4575
Frequently Asked Questions for CanBas Co
What is the CanBas Co share price?

As of 03/07/20, shares in CanBas Co are trading at ¥687, giving the company a market capitalisation of £35.4m. This share price information is delayed by 15 minutes.

How has the CanBas Co share price performed this year?

Shares in CanBas Co are currently trading at ¥687 and the price has moved by -26.76% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the CanBas Co price has moved by -28.74% over the past year.

What are the analyst and broker recommendations for CanBas Co?

Of the analysts with advisory recommendations for CanBas Co, there are there are currently "buy" , "hold" and "sell" recommendations. The overall consensus recommendation for CanBas Co is Not available. You can view the full broker recommendation list by unlocking its StockReport.

When will CanBas Co next release its financial results?

CanBas Co is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the CanBas Co dividend yield?

CanBas Co does not currently pay a dividend.

Does CanBas Co pay a dividend?

CanBas Co does not currently pay a dividend.

When does CanBas Co next pay dividends?

CanBas Co does not currently pay a dividend.

How do I buy CanBas Co shares?

To buy shares in CanBas Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of CanBas Co?

Shares in CanBas Co are currently trading at ¥687, giving the company a market capitalisation of £35.4m.

Where are CanBas Co shares listed? Where are CanBas Co shares listed?

Here are the trading details for CanBas Co:

Country of listing: Japan
Exchange: TYO
Ticker Symbol: 4575
What kind of share is CanBas Co?

Based on an overall assessment of its quality, value and momentum, CanBas Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a CanBas Co share price forecast 2020?

We were not able to load any forecast data for CanBas Co.

How can I tell whether the CanBas Co share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CanBas Co. Over the past six months, the relative strength of its shares against the market has been -21.03%. At the current price of ¥687, shares in CanBas Co are trading at -15.07% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the CanBas Co PE Ratio?

We were not able to find PE ratio data for CanBas Co.

Who are the key directors of CanBas Co?

CanBas Co's management team is headed by:

Takumi Kawabe - PRE
Makoto Katozumi - CFO
Kazuyoshi Sakamoto - OTH
Who are the major shareholders of CanBas Co?

Here are the top five shareholders of CanBas Co based on the size of their shareholding:

Bridge Capital Asset Management Co., Ltd. Corporation
Percentage owned: 9.83% (680k shares)
Morgan Stanley & Co. International Plc Research Firm
Percentage owned: 5.8% (401k shares)
Milestone Capital Management KK Corporation
Percentage owned: 3.33% (230k shares)
Omura (Akira) Individual Investor
Percentage owned: 2.95% (204k shares)
Niwa (Hiroyuki) Individual Investor
Percentage owned: 1.96% (136k shares)
Similar to 4575
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.